Clinical Trial Update: A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating TGI-5 as a monotherapy and in combination with nivolumab in locally advanced or metastatic solid tumors; recruiting for colorectal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Hepatocellular Carcinoma
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• TGI-5 (TGI-5)
• nivolumab (nivolumab)

Snippet

Sponsor: Hefei TG ImmunoPharma Co., Ltd. | Conditions: CRC (Colorectal Cancer), Melanoma (Skin Cancer) | Phase 1 | Status: RECRUITING